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Abstract 
 
Mycolic acids, which play a crucial role in the architecture of mycobacterial 
cell walls, were analyzed using electrospray ionization tandem mass 
spectrometry (ESI-MS/MS). A targeted analysis based on the 10 most 
abundant and characteristic multiple reaction monitoring (MRM) pairs was 
used to profile the crude fatty acid mixtures from Mtb and several 
nontuberculous mycobacterial strains. Comparative analysis yielded unique 
profiles for mycolic acids, enabling the reliable identification of mycobacterial 
species. In a case-control study of TB and non-TB Polish patients, we 
demonstrated the potential diagnostic utility of our approach for the rapid 
diagnosis of active TB with sensitivity and specificity surpassing those of 
existing methods. This robust method allows the identification of TB-positive 
patients after 2 h of sample preparation in the case of direct sputum analysis 
or 10 days of culturing, both of which are followed by one minute of LC-
MS/MS analysis. 
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1. Introduction 
 
Mycobacterium tuberculosis (Mtb) is an intracellular pathogen and the 
causative agent of tuberculosis (TB). Despite the discovery of the 
bacilli over 100 years ago and the availability of effective drugs for 
over 50 years, the disease still remains one of the most life-
threatening infectious diseases on earth. In 2011, there were an 
estimated 8.7 million cases of TB (13% co-infected with HIV) and 1.4 
million deaths as a result of TB infection (WHO, 2012). Furthermore, 
one third of the world’s population is latently infected with Mtb, which 
remains the largest reservoir of the tubercle bacilli.  
In the absence of an effective TB vaccine, early diagnosis and 
treatment of the active disease remains the most important part of TB 
control programs. TB diagnosis methods, which were developed over 
100 years ago, have not changed significantly for many decades. AFB 
smear microscopy, the oldest diagnostic method, detects only 
approximately 50% of active TB cases but still remains the most 
widely used test in the world. Mtb culture, the other diagnostic gold 
standard, is more sensitive than sputum smears but takes 2-6 weeks 
to produce a result (Dorman, 2012). The currently available tests 
based on DNA amplification or interferon-  release are expensive and 
require specialized equipment and qualified staff (Drobniewski et al., 
2003; Schuluger, 2001; Vittor et al., 2011). The lack of accurate, rapid 
and cheap methods for both diagnosis and drug susceptibility testing 
leaves large numbers of patients undetected and greatly hinders 
global TB control (Ottenhoff et al., 2012). 
The cell walls of Mtb, along with those of other members of the 
Mycobacterium genus, have a unique composition. Mycolic acids play 
a crucial role in the architecture of their cell envelope; these acids are 
high-molecular-weight -alkyl- -hydroxy fatty acids of exceptional 
length and complexity that are unique to mycobacteria and related 
acid-fast bacteria (Brennan and Nikaido, 1995; Takayama et al. 2005; 
Yuan et al., 1998). In Mtb, they are characterized by very hydrophobic 
C54 to C63 fatty acids with C22 to C24  side chains (Fujiwara et. al 
2012; Takayama et al. 2005). They are attached to penta-arabinose 
termini of arabinogalactan and provide a lipophilic anchorage for a 
variety of waxes and glycolipids. Mycolic acids comprise up to 30% of 
the mycobacterial cellular dry weight and are actively synthesized 
during the vegetative growth of bacteria. Most mycobacterial species 
contain a combination of different types of mycolic acids, and the 
mycolate composition of mycobacteria has been used extensively for 
taxonomic purposes. Differences in the length and chemical structure 
of mycolic acids isolated from different species suggest their possible 
use as sensitive biomarkers of mycobacterial infections.  
Over the past 20 years, much progress has been made in the 
separation and molecular characterization of mycobacterial mycolic 
acids. One of the techniques recommended by the Center for Disease 
Control (CDC) is high-performance liquid chromatography 
(HPLC)(CDC, 1996). However, this method is quite sophisticated and 
expensive relative to other laboratory techniques and is not commonly 
used in many reference laboratories. Moreover, it requires multiple 
pretreatment steps for lipid purification and a constant retention time 
for accurate results (Butler and Guthertz, 2001) More precise methods 
of mycolic acid analysis involve rapid, high-throughput mass 
spectrometry techniques that produce both qualitative and quantitative 
results (Shui et al., 2012; Song et al. 2009).  
In this work, we focused on the development of a rapid ESI-MS/MS 
technique for the identification and confirmation of TB infection on a 
triple-quadrupole instrument equipped with an ESI ion source and 
standard HPLC system. To our knowledge, this study is one of the first 
to apply ESI-MS/MS for the detection and recognition of M. 
tuberculosis mycolic acids directly in human sputum. This method is 
rapid and sensitive due to its accurate MRM transitions for the 
selected MAs and reduced sample consumption and preparation time. 
 
2. Materials and methods 
 
2.1. Reagents, solvents and standards 
 
The analysis presented in this work required high-purity reagents and 
solvents. For the LC-MS/MS mobile phase, an acetonitrile (J.T. 
Baker), methanol (Sigma-Aldrich), chloroform (J.T. Baker) and 1 M 
ammonium formate (Sigma-Aldrich) solution in water (Milli-Q, 
Millipore) was used. The compounds used for the mycolic acid 
preparation were concentrated HCl (Polish Chemical Reagents S.A. – 
POCH), Na2SO4 anhydrous (POCH) and KOH (POCH). A mycolic acid 
standard from Mycobacterium tuberculosis H37Rv (M4537) was 
purchased from Sigma-Aldrich. 
 
2.2. Bacterial/fungal strains and culturing conditions 
 
M. tuberculosis H37Rv strain (ATCC 27294), M. bovis, 12 Mtb clinical 
isolates (Clinical Division of Pulmonology and Alergology, Medical 
University of Łódź, Poland) and the non-tuberculous mycobacterial 
strains (MOTT) M. avium, M. intracellulare, M. abscessus and M. 
kansasii (Polish Collection of Microorganisms (PCM), Polish Academy 
of Sciences, Wrocław, Poland) were cultivated in 7H9 Middlebrook 
broth (Difco Laboratories Ltd., West Molesey, UK) supplemented with 
0.05% Tween 80 (Sigma) at 37°C under rotating conditions (125 rpm) 
until the mid-logarithmic phase. Bacterial and fungal strains 
(Corynebacterium glutamicum, Rhodococcus equi, Rhodococcus 
erythropolis, Proteus vulgaris, Escherichia coli, Listeria innocua, 
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Klebsiella pneumoniae, Arthrobacter sp., Pseudomonas fluorescens, 
Aspergillus nidulans, Cunninghamella elegans, Metarhizium 
anisopliae, Schizosaccharomyces pombe, Saccharomyces cerevisiae) 
from the collection of Institute of Biotechnology, Microbiology and 
Immunology, University of Lodz, Poland were cultivated as a liquid 
cultures in glucose broth medium at 37 C (bacteria) or Sabouraud 
broth in 28 C (fungi and yeasts). Bacterial CFU/ml were determined 
by plating several dilutions on Middlebrook 7H10 agar supplemented 
with OADC (mycobacteria), glucose agar (bacteria) or Sabouraud 
agar (fungi and yeasts) and counting the colonies appearing after 24h 
(bacteria), 5-7 days (fungi) or 6 weeks (mycobacteria) of incubation at 
37 C or 28 C depending on the tested microorganism. 
 
2.3. Demographics and clinical descriptions of the subjects 
 
This study analyzed 44 sputum samples collected from 44 BCG-
vaccinated HIV-negative participants. Of these subjects, 16 were adult 
patients with active pulmonary TB (12 men and 4 women) recruited 
from the Specialized Hospital of Tuberculosis, Lung Diseases and 
Rehabilitation in Tuszyn, Poland. In 13 (81%) cases, active TB was 
confirmed by sputum smear microscopy for acid-fast bacilli or the 
bacteriological isolation of M. tuberculosis. Three further TB cases 
were diagnosed based on radiological findings compatible with active 
TB, clinical symptoms and responses to anti-TB treatment. The 
sputum samples were collected before or during the first 2 weeks of 
treatment. As controls, 17 adult non-TB patients (12 men and 5 
women), hospitalized with pulmonary symptoms but eventually 
diagnosed with pulmonary diseases other than TB (11 bacterial 
pneumonia, 3 lung cancer, 3 bronchitis), along with 11 healthy 
controls (5 men and 6 women) were included in the study. None of 
these individuals had any known history of contact with TB and 
showed negative TB bacteriology. The sputum collection and the 
study followed the ethical guidelines of the Specialized Hospital of 
Tuberculosis, Lung Diseases and Rehabilitation in Tuszyn, Poland. 
 
2.4. Sputum processing 
 
Sputum specimens (2 ml) were mixed with equal volumes of NaOH-N-
acetyl cysteine solution (4% NaOH, 1% N-acetyl cysteine) and left at 
37 C for 30 min with occasional vortexing. Subsequently, 4 ml of 2.9% 
sodium citrate and 8 ml of sterile 0.067 M phosphate buffer (pH 6.8) 
were added. After centrifugation (3500 rpm, 20 min), the supernatants 
were decanted and the pellets were used for (1) the preparation of 
smears for standard Ziehl-Neelsen staining, (2) direct extraction of 
mycolic acids for LC-MS/MS analysis, (3) inoculation into 7H9 
Middlebrook broth supplemented with 0.05% Tween 80 and incubation 
for 10 days at 37 C (indirect LC-MS/MS analysis) and (4) inoculation 
onto Löwenstein-Jensen agar slants and culture for 4-6 weeks at 
37 C. When colonies were grossly observed on the surface of the 
Löwenstein-Jensen medium, M. tuberculosis species were confirmed 
and verified using acid-fast staining and niacin testing. 
 
2.5. Mycolic acid extraction from bacteria and human sputum 
 
The extraction procedure was based on previously published methods 
using alkali hydrolysis (CDC, 1996; Butler and Guthertz, 2001). The 
initial mycolic acid isolation procedure involved 18 modifications 
including the influence of cell pretreatment (surface lipids methanol 
extraction and removal), alkali hydrolysis  (KOH concentration, 
temperature, incubation time) as well as the MAs extraction procedure 
(extraction solvent, volume, time and number of repeats). Every 
modification was checked multiple times to determine its repeatability 
and reproducibility. The optimized method was significantly more 
sensitive and robust than the initial method and consisted of the 
following steps: a Mycobacterium cell suspension (10
7
 cells/ml) or pre-
prepared sputum were transferred into a twisted glass vial and 
centrifuged (3500 rpm; 10 min; 4°C). The obtained cell sediment was 
re-suspended in 2 ml of methanol, shaken on vortex for 30 s and 
centrifuged again as described above. The methanol was then 
decanted from the cell sediment and the cells were re-suspended in 2 
ml of 25% KOH in methanol. The bacterial cell suspensions were 
incubated at 90°C for 1 h in tightly closed glass vials. After cooling to 
room temperature and acidification with 1.5 ml of concentrated HCl 
(38%), the samples were extracted 3 times with 2 ml of chloroform (30 
s on vortex, 3000 rpm). Water aliquots were removed from the 
extracts by the addition of anhydrous sodium acetate and evaporated 
to dryness under a vacuum evaporator. The dry residue was dissolved 
in 1 ml of chloroform or LC-eluent and transferred to HPLC vials for 
LC-MS/MS analysis. 
 
 
 
 
2.6. LC-MS/MS analysis 
 
Flow injection analysis (FIA) was used to detect and profile the 
mycolic acids. The FIA-LC-MS/MS analyses were performed on an 
Agilent 1200 LC system coupled with an AB Sciex 3200 QTRAP mass 
detector. The liquid chromatography parameters were as follows: 
injection volume, 10 µl; draw speed, 200 µl/min; eject speed and 
eluent flow, 400 µl/min. The mobile phase consisted of 
methanol:chloroform:acetonitrile (20:40:40) with the addition of 5 mM 
ammonium formate. The needle was washed for 3 s in chloroform in 
the flush port after every injection. The mass detector was set to a 
negative ionization MRM mode with an ESI (Turbo V) ion source. The 
optimized ion source parameters were as follows: curtain gas, 10; IS, -
4500 V; temperature, 650 °C; GS1, 50; GS2, 65. The optimized 
compound-dependent parameters for 10 MRM are shown in table 1. 
The entire method involves 1 min of analysis time. The injection cycle 
applied for system cleaning and conditioning consisted of the following 
injections and method runs: 100 µl of chloroform, 10 µl of the blank 
and 10 µl of the tested sample. 
 
2.7. Statistical analysis 
 
The average intensity of the MRM signals for the 10 mycolic acids 
listed in the Table 1 was calculated by a chromatogram averaging 
from 0.01 to 0.3 min of the LC run. Each MRM pair percentage was 
calculated as the percent of the intensity related to the corresponding 
MRM sum of the tested sample (100% intensity). Statistical analyses 
were performed using the calculated intensity percentages 
transformed using the arcus sinus function. These values directly 
correspond to the composition percentage of all 10 chosen mycolic 
acids.  
To confirm homogeneity of each mycolic acid content within 
the pattern isolated from Mtb species and extracted from sputum 
samples, Student's t-test for the comparison of two means was 
performed. Average intensities for each mycolic acid content were 
firstly transformed by arcus sinus function for all samples in both 
groups: Mtb species (n=12) and extracted sputum samples (n=16). 
Then average and standard deviation values inside groups were 
calculated and compared using Student's t-test for the comparison of 
two means. The presented results are confidence interval 95% of 
differences between two means for each analyzed mycolic acid 
separately. 
 
3. Results 
 
3.1. Mycobacterial mycolic acids profiles 
 
The ESI-MS/MS conditions were optimized using a mycolic acid 
standard from a virulent Mtb strain (M4537, Sigma-Aldrich). Initially, 
we focused on the analysis of the fragmentation pattern of the MAs by 
Q1 scans, precursor ion scans, product ion scans and MS
3
 scans to 
confirm the structure of the MA chains postulated by other authors 
(Figure 1). The most significant data came from the product ion and 
MS
3
 experiments (Figure 1C and 1D). Fragments coming from the 
cleavage of C-C bond between carboxyl α-alkyl chain and hydroxyl 
meromycolic chain in the range of 300 to 430 m/z are most intensive 
and characteristic fragmentation pattern for MAs. To confirm the C-C 
cleavage between the MAs chains, we focused on the 600-900 m/z 
region, where we found very weak but detectable fragments coming 
from the corresponding meromycolic chains.  
 
 
As an example, figure 1C shows the fragmentation of α-MA (1164.6 
m/z, C80H153O3), where the peaks for the C26, C24 and C22 carboxyl α-
alkyl chains are at 395.5 m/z, 367.5 m/z and 339.4 m/z, respectively, 
and those for the C54, C56 and C58 meromycolic chains are at 768.2 
m/z, 796.5 m/z and 824.4 m/z, respectively. Similar fragmentation 
schemes were observed in all tested MAs (data not shown), including 
methoxy- and keto- forms. Further fragmentation of the base peaks (α- 
Table 1. Most of the characteristic mycolic acid MRM pairs chosen for diagnostic purposes and 
their MS/MS compound-dependent parameters: Q1 – precursor mass, Q2 – product ion mass, 
Time – dwell time (ms), DP – declustering potential, EP – entrance potential, CEP – collision cell 
entrance potential, CE – collision energy, CXP – collision cell exit potential. 
 
Mycolic 
acid form 
Chemical 
formula 
Q1 
mass 
[m/z] 
α-branch 
Q3 mass 
[m/z] 
Time 
(ms) 
DP EP CEP CE CXP 
α- C78H152O3 1136.4 C24 395.4 40 -155 -9.5 -84 -84 -3 
α- C78H152O3 1136.4 C22 367.3 40 -155 -9.5 -84 -74 -3 
α- C80H156O3 1164.4 C24 395.4 40 -155 -9.5 -60 -86 -3 
α- C82H160O3 1192.3 C24 395.4 40 -155 -10 -48 -88 -3 
α- C84H164O3 1220.3 C24 395.4 40 -155 -10 -66 -82 -3 
methoxy- C85H168O4 1252.3 C24 395.4 40 -155 -9 -72 -82 -3 
methoxy- C85H168O4 1252.3 C22 367.3 40 -155 -9 -72 -80 -3 
keto- C86H168O4 1264.4 C24 395.4 40 -160 -9 -34 -84 -3 
keto- C87H170O4 1278.4 C24 395.4 40 -160 -9.5 -50 -84 -3 
methoxy- C87H172O4 1280.4 C24 395.4 40 -160 -10 -54 -88 -3 
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Fig. 1. MS/MS analysis of MAs structures. A, Q1 scan (blue) against 
the precursor ion scan for 395.5 m/z (red) in the scan range of 1100–
1400 m/z. B, Precursor ion scan for 377.5 m/z (blue) and 367.5 m/z 
(red) in the scan range of 1100–1400 m/z. C, Example EPI scan of 
MS 1164.6 m/z. D, Example MS3 results for the most abundant 
fragmentation ions from 1164.6 m/z MA. E, Proposal of the mass 
spectra interpretation of 1164.6 m/z MA. 
 
alkyl chains) is a result of rearrangement leading to H2O loss from 
carboxyl groups resulting in the formation of 377.5 m/z (C26 chain), 
349.5 m/z (C24 chain) and 321.6 m/z (C22 chain) ions. This mechanism 
is strongly supported by the MS
3
 results for the MAs (Figure 1D). In 
the case of the 377.5 m/z MS
3
 experiment, we also observed 375.5 
m/z, 357.4 m/z and 323.6-325.5 m/z ions. We suppose that after the 
initial double deprotonation of the 377.5 m/z ion, resulting in the 
formation of the 375.5 m/z ion, the loss of a second H2O molecule or 
C3O radical occurs. This fragmentation generates the ions observed at 
357.4 m/z and 323.6 m/z. The other MS
3
 experiments (data not 
shown) did not produce any reasonable results, most likely because of 
the very low intensities observed for the EPI spectrum ions (Figure 
1C). The fragmentation pattern observed in the 377.5 m/z MS
3
 
experiment proved our initial suspicion that the fragmentation of α-
alkyl chains is the result of succeeding rearrangements, beginning 
with the charged α-carbon and carboxyl group.  
Qualitative analysis of the mass spectra of mycolic acids led to the 
development and optimization of an MS/MS method containing 60 
MRM pairs. For further study, we chose only the 10 most abundant 
and characteristic MRM pairs reflecting the presence of α, keto and 
methoxy-mycolic acids best suited for TB diagnostics (Table 1). 
Although the full LC-MS/MS method was not used as a standard 
quantitation method, we verified its basic parameters for all 10 MRM 
pairs. The weakest MRM transition LOD was 1 ng/ml, and linearity in 
all cases (r≥0.995) ranged from 1 to 100 ng/ml. 
The potential matrix effect on the mycolic acid extraction and 
identification was evaluated by analyzing three samples: (1) the 
sputum of a healthy control volunteer, (2) the sputum of a healthy 
control volunteer inoculated in vitro with 10
8
 M. tuberculosis H37Rv 
cells/ml, (3) 10
8 
cells/ml suspension of M. tuberculosis H37Rv prepared 
in 7H9 Middlebrook medium. The results indicated no influence of the 
matrix on the intensity and profile of the mycolic acids using the 
applied extraction and LC-MS/MS method. 
Further analysis focused on the ability of the tested method to 
differentiate between Mycobacterium species. As shown in table 2, the 
mycolic acid profiles of MOTT strains are significantly different from 
those of Mtb H37Rv and M. bovis BCG strains. Two MRM transitions, 
1136/367 and 1252/367, are the most specific for the identification of 
the selected MOTT species because these species feature C24-long α-
alkyl chains, whereas the other analyzed mycolic acids include C26-
long α-alkyl chains. Within the tested MOTT strains, the mycolic acid 
profile can be used to identify M. avium and M. kansasii not M. 
abscessus and M. intracellulare, as there are no significant differences 
in the mycolic acid profiles of these strains. 
Studies of the local Mtb population were performed by comparative 
analysis of the clinical Mtb isolates and TB patients. Statistical 
analysis of the difference in the average intensity for each mycolic 
acid content in the two groups was based on Student's t-test for the 
comparison of the two means. Mean differences in each mycolic acid 
content in one group were subtracted from the values for the tested 
mycolic acid in the second group. Statistical significance of differences 
is shown as confidence intervals 95% (CI95) for the comparison of the 
two means. CI95, which does not include 0, represents a statistically 
significant difference between two groups. As presented in Figure 2, a 
significant difference was observed only in case of three compounds 
(1252/367, 1264/395, 1220/395 MRM pairs), which highlights the 
possible range of characteristic mycolic acid profiles for all Mtb strains. 
Despite the slight differences in the percentage of individual mycolic 
acids from clinical Mtb strains or the virulent reference H37Rv strain, a 
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Mtb “fingerprint” is still easily identified and distinguished (Figure 3). 
Unfortunately, the data do not allow M. bovis BCG and M. tuberculosis 
strains to be distinguished. 
The extraction of mycolic acids was also performed from bacteria 
within Corynebacterineae suborder not belonging to the 
Mycobacterium genus, in which shorter-chain mycolic acids naturally 
occur in the cell wall as well as bacteria not belonging to the 
Corynebacterineae suborder, selected microscopic fungi and yeasts. 
The obtained results supported the high specificity of the applied LC-
MS/MS method, with no false positive results for any of the tested 
extracts from the selected strains (Table S-1 in Supplementary 
material). 
 
 
3.2. Clinical sample analysis 
 
LC-MS/MS analysis of 16 sputum samples obtained from TB patients 
indicated the presence of Mtb mycolic acids in 11 (69%) specimens 
directly or 15 (94%) specimens after 10 days of incubation. In contast, 
the presence of AFB bacilli was confirmed in 9 out of 16 (56%) TB 
patients, whereas M.tb culture was positive for 13 (81%) specimens. 
No signal was measured in the sputum from non-TB patients or 
healthy controls, suggesting that this method is very specific with no 
cross-reactivity. Using our method we also detected mycolic acids of 
Mtb in a 10-day incubated sputum from TB patients with negative 
smear and culture results (material no. 13, 14, 15). However, we 
observed one false negative result in a patient with confirmed TB 
(material no.16), suggesting that our method needs improvement in 
terms of mycolic acid extraction efficiency or instrument sensitivity 
(Table S-2 in Supplementary material). Examples of the raw LC-
MS/MS data are presented in figure 4.  
 
4. Discussion. 
 
Mycolic acid profiles can be used as a tool for the classification of the 
infecting mycobacteria (CDC, 1996; Butler and Guthertz, 2001, Shui et 
al., 2012); however, for our purposes, the most important was the fact 
that Mtb mycolic acid profile is unique and can be used as a 
diagnostic marker for TB confirmation or exclusion in clinical samples. 
On the other hand, the proper identification of MOTT species seems 
to be critical, as some species are known to be naturally resistant to 
one or more anti-TB drugs. 
 
 
 
Fig. 2. Statistical analysis of differences in the MA content obtained 
from TB patients from extracted sputum (n = 16) and Mtb clinical 
isolates (n = 12). Figure presents mean results of the Student's t test 
for the comparison of the 2 means (groups) in the case of each MA 
separately with CI95. 
 
 
 
 
Fig. 3. Differences in MAs profiles between clinical isolates (n = 12) 
and reference strains of Mtb and M. bovis BCG. The values are the 
percentages of the average intensity for each MA to the total intensity 
of all analyzed compounds with a CI95. 
 
Mass spectra analyses presented in this work prove the structure of 
MAs postulated by other authors. Similar results and mass spectra 
interpretations based only on precursor ion scans were presented by 
Song et al., 2009
 
and Shui et al., 2012. The precursor ion scan (Figure 
1A and 1B) showed that the C26 chain is the dominant α-alkyl chain in 
the mycolic acid profile of Mtb H37Rv. Although there are many 
recognized species of Mycobacteria  the domination of the C26 chain 
seems to be characteristic of Mtb which cause active TB in humans 
(Song et al., 2009) therefore it is possible to differentiate between Mtb 
and MOTT group only the basis of the α-mycolic chain length. In our 
method MRM pairs including a longer (C26) α-mycolic chain (Q3 mass 
- 395 m/z) were used to confirm the presence of Mtb while MRM pairs 
built on a shorter (C24) α-mycolic chain determination (Q3 mass - 367 
m/z) let us check the presence of MOTT strains. The differences 
between the 10 MRM pairs chosen for TB diagnostics in our study and 
the 14 chosen by Shui et al., 2012 are the use of 1220 and 1278 m/z 
in our approach and 1196, 1224 and 1208 m/z their approach. 
Additionally, we chose two Q3-367 m/z-based MRMs, whereas Shui et 
al., 2012 choose three of this type of MRM transitions for the final 
diagnostic method. The use of different mycolic acid patterns in the 
Mtb diagnostics in our work did not affect data acquisition and 
interpretation. 
Mycolic acids are important part of the cell wall for a wide group of 
microorganisms within Corynebacterineae suborder. These 
compounds are characterized by a variety in size and structure of the 
aliphatic chains. As it was shown by Kowalski et al. (2012) the total 
carbon of MAs from Mtb covers the range 70-90 and only 
Tsukamurella genus has a potential for a cross-talk with Mtb species 
as it covers the range 64-78 in general. However, within the chosen 
10 MRM pairs (Table 1) the lowest number of carbon atoms in the 
analyzed mycolic acid moiety is 78. The only one environmental 
isolate without any clinical significance, described as T. 
carboxydivorans poses a similar range of the total carbon atoms (Park 
et al. 2009), but overlapped range of the total carbon atoms do not 
have to lead to the cross-signal as Tsukamurella genus is also 
characterized by highly unsaturated (up to 8 double bonds) 
meromycolic chain without any functional groups (Yassin et al. 1996). 
In the case of Mycobacterium there are three potential locations where 
double bonds could appear in alpha mycolic acids and also three 
places where functional groups could appear in keto- or metoxy- 
mycolic acids. Considering the double filtering of the m/z in the MRM 
scan mode, MRM pairs selection in the final method and data 
presented in table S-1 (Supplementary material) we think it is highly 
unlikely to obtain false positive signals from other organisms than 
Mycobacterium. 
Although mycolic acids are ideal conservative compounds for Mtb 
confirmation studies, some territory, culturing, time of growth or 
physiological state related differences in their compositions were 
observed. Experimental data demonstrated that mycolic acids from 
Mtb, consisting mainly of alpha-, keto-, and methoxy-mycolates, 
contain mixtures of homologs with different chain lengths or 
stereochemistries around the functional groups in the main chain 
(Beukes et al. 2010). These variables can possibly cause slight 
differences in the content of the single mycolic acid. However, 
variability could be omitted during analysis of the mycolic acid pattern 
consisting of 10 different mycolic acids – e.g. characteristic for 
Mycobacterium tuberculosis presence. Accurate and high-throughput 
analysis of mycolic acids patterns form clinical samples from all over 
the world as well as reference species collected in microorganisms  
Table 2. Mycolic acid profiles of Mtb and Ntm reference strains. 
 
Mycolic 
acids 
Mtb Ntb 
M. 
tuberculosis 
M. bovis 
BCG 
M. 
kansasii 
M.  
avium 
M. 
intracellulare 
M. 
abscessus 
1136/395 14.96% 16.50% 0.53% 0.47% 0.07% 0.37% 
1136/367 3.30% 3.32% 53.74% 29.60% 98.41% 97.67% 
1164/395 18.17% 20.21% 1.11% 2.38% 0.26% 0.43% 
1192/395 11.60% 11.25% 1.13% 12.17% 0.15% 0.22% 
1220/395 5.35% 4.47% 0.45% 6.16% 0.18% 0.09% 
1252/395 12.58% 13.17% 0.67% 0.97% 0.29% 0.22% 
1252/367 2.99% 2.86% 39.44% 35.53% 0.32% 0.19% 
1264/395 6.53% 8.14% 0.28% 2.45% 0.00% 0.15% 
1278/395 6.84% 0.40% 1.81% 8.01% 0.11% 0.19% 
1280/395 17.68% 19.69% 0.85% 2.24% 0.19% 0.47% 
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Fig. 4. Typical positive (A), unsure (B), and negative (C) results for 
LC-MS/MS analysis. 
 
banks could be the source of future results leading to a creation of 
global standards for mycolic acids patterns typical not only for Mtb but 
also for each species of atypical mycobacteria. 
The diagnosis of TB infection or drug efficacy studies with mass 
spectrometry involve different approaches. Matrix-assisted laser 
desorption ionization time of flight mass spectrometry (MALDI-TOF-
MS) is used in proteomic or/and intact cell analysis. The MALDI-TOF-
MS whole proteome analysis conducted by Wang et al. showed that 
proteins are useful biomolecules for the differentiation of 
mycobacterial strains; however, this analysis is not highly specific 
because of the matrix proteins and noise issues. Similar methods 
were used by El Khéchine et al., 2011 and Shitikov et al., 2012 again, 
the targeted protein analysis was only applicable to previously 
cultured mycobacteria cells. Intact cell analysis by MALDI-TOF MS 
incorporates analysis of all compounds coming from the laser-ionized 
cell envelopes. A mass spectra fingerprint can be used for diagnostic 
purposes for mycobacterial cultures (Lotz et al., 2012; Saleeb et al. 
2011). MS methods are robust, fast, cheap and effective but also 
require bacteria culturing, which can take between 1 day and 2 
months depending on the tested species. Thus, they can be 
successfully applied in drug efficacy studies but are less desirable for 
diagnostic work. To our knowledge, the work published by Deng et al. 
is the first to use MALDI-TOF-MS to analyze clinical samples, but the 
developed method combines standard methods and MS/MS analysis. 
The authors analyzed blood samples with respect to the presence of 
amyloid A and transthyretin using ELISA testing and neopterin and C-
reactive proteins by MALDI-TOF-MS. The results from both tests were 
used for the estimation of active pulmonary TB. The test exhibited 
85.7% sensitivity and 83.3% specificity. Sample preparation using 
weak cation ion exchange magnetic beads and the authors’ 
suggestion to use 2-D electrophoresis instead make this method too 
complex for routine analysis. 
Mycolic acids as a biomarker seem to be most appropriate for 
diagnostic purposes as they occur in high concentration in the cell 
walls of mycobacteria, regardless of growth conditions, and are 
relatively easy to extract. MS/MS analysis of the MA profiles in MRM 
mode is the most successful method for the TB diagnoses in patient 
sputum or cell cultures, as described in our work or by Shui et al., 
2012. The presented results obtained using LC-MS/MS analysis are 
better than those obtained using the current TB diagnostic methods 
with one powerful advantage: the possibility of detecting and 
recognizing Mtb within the same day (2 h for sample preparation and 
1 min for LC-MS/MS analysis) or, at worst, 10 days from the start  
 
of the test. In contrast, 3 to 6 weeks are required for the detectable 
growth of Mtb on solid media due to the long doubling time of the 
bacteria. Although acid-fast staining of clinical material remains the 
simplest and most frequently used microbiological test for TB 
detection, the major limitation is its poor sensitivity. Sputum smear 
examination for acid-fast bacilli allow diagnosing up to 50% of TB 
cases, whereas a sputum culture can confirm pulmonary TB in around 
80% of true cases (Siddiqi et al., 2003). However, the detection of 
acid-fast bacilli in a sputum smear is not affirmative for Mtb, because 
many nontuberculous mycobacteria may also lead to positive AFB 
staining results (Jafari et al., 2006). The overall sensitivity of the direct 
ESI-MS/MS analysis of mycolic acids (69%) in our study was similar to 
the sensitivity of the sputum smear, however it was significantly 
improved after a 10-day incubation period (94%). Using our method 
we detected Mtb mycolic acids also in the sputum of patients with 
negative bacteriological results. Although smear-negative patients are 
less infectious than patients with bacteriology confirmed TB, they also 
contribute to the transmission of TB (Behr et al., 1999). Light 
microscopy can detect mycobacteria in the sputum at a minimum 
density of 5000-10000 bacterial cells per ml of specimen, whereas the 
infectious dose is only a few mycobacterial cells. Therefore, people in 
contact with smear-negative TB patients are also at risk of M. tb 
infection and subsequent development of active TB disease 
(Tostmann et al., 2008). However, it must be stated that these 
promising results should be confirmed on a larger group of TB patients 
with negative bacteriology results. We think that the technique might 
be also useful in the diagnosis of TB forms other than pulmonary, 
especially those in which it is not possible to detect mycobacteria 
using traditional diagnostic methods. 
The MRM-based method developed by Shui et al., 2012 requires 2,5-
day sample preparation followed by rapid (2 min) MS/MS analysis and 
exhibits 94% sensitivity and 93% specificity; however, only 25% of 
smear-negative patients produced positive MAs signals. In contrast, in 
our work, positive MAs signals were produced by 43% of the smear-
negative patients in direct sputum analysis and 86% after 10-day 
culturing. In both cases, positive bacterioscopy resulted in 100% 
confirmation by MS/MS methods regardless of the number of bacteria 
cells observed. Similar MAs extractions to those presented in this 
work were applied by Viader-Salvadó et al., 2007; however, the 
measurement of MAs was performed on HPLC with fluorescence 
detection during a 15 min gradient (methanol:chloroform) analysis with 
a 2.5 ml/min flow rate. The obtained results did not significantly extend 
the specificity or sensitivity relative to the standard AFB staining 
method.  
Novel TB diagnosis methods involve genetic analysis of DNA or RNA 
(Daley et al., 2008; Toney et al., 2010). Xpert MTB/RIF assay is an 
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example of a sensitive, specific and rapid PCR-based method (Chang 
et al., 2012; Lawn et al., 2011). The specificity of the test is 99%; the 
sensitivity for smear-positive patients is in the range of 97.9-98.4%, 
whereas that for bacterioscopy-negative patients is 73.1%. This 
method is also used for rifampicin resistance tests. MTB/RIF assay is 
currently recommended by WHO for TB diagnosis. 
The initial cost of the LC-MS/MS equipment is relatively high; 
however, the per sample costs for our method are much less than 
those for DNA-based techniques because we use only common 
reagents for sample preparation and analysis, whereas molecular 
methods require expensive hybridization probes or primers. The 
estimated cost of the sample analysis (including only consumables 
and reagents) performed with our method is approximately $0.60 per 
sample. The final cost of the test may vary depending on the country 
currency, personnel costs, equipment amortization and service, but 
the overall cost will likely be competitive with those of conventional 
and genetic methods. Considering the cost of the LC-MS/MS 
apparatus, genetic methods are preferred as a novel diagnostic tool; 
however, with the current progress in clinical applications, an 
increasing number of laboratories are using MS/MS techniques in 
various tests. Presented results, although preliminary and based on a 
limited number of tested samples, look very promising and in the 
future studies should be done including more patients. We see a huge 
potential for the developed method in clinical laboratories or hospitals 
already having or planning to buy LC-MS/MS instrumentation as it can 
be applied not only for Mtb detection but also for other mycobacterial 
infection confirmations and drug efficacy studies.  
 
5. Conclusion 
 
In summary, a rapid, reliable, robust and relatively low-cost diagnostic 
technique developed by our group is an attractive alternative for rapid 
TB diagnosis, which is one of the most difficult challenges facing 
clinicians. It is estimated that each person with untreated TB infects an 
average of between 10 and 15 people every year, remaining a 
reservoir from which active TB can develop. Currently, conventional 
methods require an average of 3-6 weeks to obtain a result, which 
leads to delays in the introduction of effective treatments to stop the 
spread of M. tuberculosis in the environment and reduce the rate of 
transmission. 
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Table S-1. Control microorganisms other that Mycobacterium checked 
for presence of mycolic acid using LC-MS/MS method. 
 
Bacteria Fungi Yeast 
Corynebacterium glutamicum  Aspergillus nidulans Schizoaccharomyces pombe 
Rhodococcus equi  Cunninghamella elegans Saccharomyces cerevisiae 
Rhodococcus erythropolis Metarhizium anisopliae  
Proteus vulgaris   
Escherichia coli    
Listeria inocua   
Klebsiella pneumoniae    
Arthrobacter sp.   
Pseudomonas fluorescens   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S-2. Summary of the clinical samples tests. 
 
Group Material 
number 
AFB 
smear 
stain 
Mtb 
culture 
LC-MS/MS analysis 
direct after 10 days of 
incubation 
TB patients 
1 positive positive  positive positive  
2 positive positive  positive positive  
3 positive positive  positive positive  
4 positive positive positive positive 
5 positive positive  positive  positive  
6 positive positive  positive  positive  
7 positive positive positive positive 
8 positive positive positive positive 
9 positive positive positive positive 
10 negative positive positive positive  
11 negative positive positive positive 
12 negative positive negative positive 
13 negative negative  negative positive  
14 negative negative  unsure positive positive  
15 negative negative  negative positive  
16 negative positive negative negative 
Non-TB 
patients 
17 negative negative negative negative 
18 negative negative  negative  negative  
19 negative negative  negative  negative  
20 negative negative  negative  negative  
21 negative negative  negative  negative  
22 negative negative  negative  negative  
23 negative negative  negative  negative  
24 negative negative  negative  negative  
25 negative negative  negative  negative  
26 negative negative  negative  negative  
27 negative negative  negative  negative  
28 negative negative  negative  negative  
29 negative negative  negative  negative  
30 negative negative  negative  negative  
31 negative negative  negative  negative  
32 negative negative  negative  negative  
33 negative negative  negative  negative  
Control 
subjects 
34 negative negative negative  negative  
35 negative negative negative  negative  
36 negative negative negative  negative  
37 negative negative negative negative 
38 negative negative negative negative 
39 negative negative negative negative 
40 negative negative negative negative 
41 negative negative negative negative 
42 negative negative negative negative 
43 negative negative negative negative 
44 negative negative negative negative 
 
 
